Purpose: To retrospectively review the efficacy and safety of image-guided linear accelerator-based radiosurgery for spinal hemangioblastomas.
Methods: Between August 2004 and September 2010, nine patients with 20 hemangioblastomas underwent spinal radiosurgery. Five patients had von Hipple-Lindau disease. Four patients had multiple tumors. Ten tumors were located in the thoracic spine, eight in the cervical spine, and two in the lumbar spine. Tumor volume varied from 0.08 to 14.4 cc (median 0.72 cc). Maximum tumor dimension varied from 2.5 to 24 mm (median 10.5 mm). Radiosurgery was performed with a dedicated 6 MV linear accelerator equipped with a micro-multileaf collimator. Median peripheral tumor dose and prescription isodose were 12 Gy and 90%, respectively. Image guidance was performed by optical tracking of infrared reflectors, fusion of oblique radiographs with dynamically reconstructed digital radiographs, and automatic patient positioning. Follow-up varied from 14 to 86 months (median 51 months).
Results: Kaplan-Meier estimated 4-year overall and solid tumor local control rates were 90% and 95%, respectively. One tumor progressed 12 months after treatment and a new cyst developed 10 months after treatment in another tumor. There has been no clinical or imaging evidence for spinal cord injury.
Conclusions: Results of this limited experience indicate linear accelerator-based radiosurgery is safe and effective for spinal cord hemangioblastomas. Longer follow-up is necessary to confirm the durability of tumor control, but these initial results imply linear accelerator-based radiosurgery may represent a therapeutic alternative to surgery for selected patients with spinal hemangioblastomas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424669 | PMC |
http://dx.doi.org/10.4103/2152-7806.98386 | DOI Listing |
Cancers (Basel)
January 2025
Istituto Nazionale di Fisica Nucleare, Sezione di Bari, 70125 Bari, Italy.
Background: Boron neutron capture therapy (BNCT) is an innovative binary form of radiation therapy with high selectivity towards cancer tissue based on the neutron capture reaction B(n,α)Li, consisting in the exposition of patients to neutron beams after administration of a boron compound with preferential accumulation in cancer cells. The high linear energy transfer products of the ensuing reaction deposit their energy at the cell level, sparing normal tissue. Although progress in accelerator-based BNCT has led to renewed interest in this cancer treatment modality, in vivo dose monitoring during treatment still remains not feasible and several approaches are under investigation.
View Article and Find Full Text PDFAppl Radiat Isot
January 2025
Kyoto University Graduate School of Engineering, Kyoto Daigaku-katsura, Nishikyo-ku, Kyoto, 615-8530, Japan.
We aimed to explore the possibility of realizing a beam shaping assembly (BSA) driven by a 15-kW beam of 33-MeV electrons of an electron linear accelerator (LINAC) when a boronophenylalanine is adopted as a boron carrier. Simulation calculations were performed to design two types of BSAs driven by the small LINAC. The one was an experimental BSA, and the other was a high-performance BSA.
View Article and Find Full Text PDFFront Oncol
November 2024
Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
Objective: To assess the efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy (LINAC-FSRT) in patients with brain metastases (BM).
Methods: We retrospectively analyzed 214 patients treated with LINAC-FSRT, categorized based on biologically effective dose (BED10, / = 10) into two groups (≤55 Gy, >55 Gy). Stratified analyses were conducted based on targeted therapy to compare survival outcomes.
J Appl Clin Med Phys
December 2024
Department of Radiation Oncology, Willis Knighton Cancer Center, Shreveport, Louisiana, USA.
Linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) has become a mainstay in the management of intracranial tumors. However, the high fractional doses and sharp gradients used in SRS place heavy demands on geometric accuracy. Image guidance systems such as ExacTrac (ETX, Brainlab AG, Munich, Germany) have been developed to facilitate position verification at nonzero table angles.
View Article and Find Full Text PDFSci Rep
November 2024
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization Building, Next to the Milad Tower, Hemmat Exp. Way, P.O.Box:14665-1157, Tehran, Iran.
X-irradiation of blood products is an alternative for gamma-ray to prevent post-transfusion GvHD. However, commercial X-irradiators are not widely available while little is known about their safety and efficacy for platelet products. This study introduces an efficient, accessible and cost-effective "X irradiation system" for platelet concentrates (PCs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!